sickling smoothly through life… educating patients about transition nirmish shah, md assistant...

45
Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke University

Upload: melissa-mccoy

Post on 26-Dec-2015

213 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Sickling smoothly through life…

Sickling smoothly through life…

Educating patients about transition

Educating patients about transition

Nirmish Shah, MDAssistant Professor

Director of Sickle Cell Transition ProgramDuke University

Page 2: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Outline

Introduction

Challenges facing transitioning SCD patients

Model and key components for a successful transition to adulthood

‘Who, What, Where’ – levels of patient understanding

2

Page 3: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Who

Medicine-Pediatrics residency at ECU– 2000-2004– Goal was to do med/peds hem/onc…. ….then reality kicked in and hematology seemed more realistic and interesting

Page 4: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

What

Med/Peds Hematologist– Joint appointment between medicine and pediatrics– Have outpatient clinics in both medicine and pediatrics– Do inpatient consults for adult hematology– Majority of effort in research

Page 5: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Where

‘Where do I go’…– Goal to perform combined pediatric and adult research– Improve transition guidelines and protocols– Advocate co-management of SCD with primary care

providers

Page 6: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Introduction

Sickle Cell Disease (SCD) is the most common inherited disease worldwide

Recent advances include prophylactic PCN, improved immunizations, and increased use of hydroxyurea

Page 7: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Survival

Deaths due to sickle cell anemia or sickle cell trait in 1967

Scott, R. Health Care Priority and Sickle Cell Anemia, JAMA, 1970, 214(4)

Page 8: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Recent Developments Have Greatly Improved Patient Management and Survival1

8

1. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Blood. 2010;115(17):3447–3452. 2. National Heart, Lung, and Blood Institute. Progress in Heart, Lung, and Blood Research: Reducing the burden of Sickle Cell Disease. August, 2011. https://www.nhlbi.nih.gov/news/spotlight/success/sicklecell.pdf. Accessed April 21, 2014. 3. Elmariah H, Garrett ME, De Castro LM, et al. Am J Hematol. 2014;89(5):530-535. 4. Zhou Z, Behymer M, Guchhait P. Anemia 2011;2011:918916. 5. Lusher JM, Haghighat H, Khalifa AS. Am J Hematol. 1976;1(2):265-273. 6. National Heart, Lung, and Blood Institute. The Management of Sickle Cell Disease. 4th ed. Bethesda, MD: National Institutes of Health; 2002. NIH publication 02-2117. http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf. Accessed April 9, 2014. 7. Wang WC, Ware RE, Miller ST, et al. Lancet. 2011;377(9778):1663–1672. 8. Ware RE, Helms RW. Blood. 2012;119(17):3925-3932.

BABY HUG, Pediatric Hydroxyurea Phase III Clinical Trial; NIH, National Institutes of Health; STOP, Stroke Prevention Trial in Sickle Cell Anemia.

60

50

40

30

20

10

Life

exp

ecta

ncy

for

patie

nts

with

SC

A (

year

s)2

,3

1910 1950 1970 1980 1990 2000 201019601920 1930 1940

1910 - Discovery of SCD4

1986 – Antibiotic prophylaxis in infants6

1949 – Identification of HbS4

1976 – RBC transfusion for treatment of secondary stroke5

1987 – NIH recommends newborn screening6

1998 – STOP trial6

2011 – BABY HUG trial7

2012 – SWiTCH trial8

1995 – MSH Trial6

Page 9: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

CHALLENGES FACING TRANSITIONING SCD PATIENTS

Page 10: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Transitioning Poses Many Challenges for Patients

10

1. Treadwell M, Telfair J, Gibson RW, et al. Am J Hematol. 2011;86(1):116-120. 2. Paulukonis S, Neumayr L, Coates TD, et al. Blood. 2010;116:Abstract 254. 3. McDonnell WM, Kocolas I, Roosevelt GE, Yetman AT. Arch Pediatr Adolesc Med. 2010;164(6):572-576. 4. National Heart, Lung, and Blood Institute. The Management of Sickle Cell Disease. 4th ed. Bethesda, MD: National Institutes of Health; 2002. NIH publication 02-2117. http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf. Accessed August 23, 2013.

Challenges for Any Patient With a Chronic Condition1-2

• Inability to effectively manage their disease

• Need for effective coping strategies

• Concerns about cost of care and insurance coverage

• Uncertainty about future as an independent adult

Challenges of Particular Concern for SCD Patients1-4

• Increased socioeconomic challenges

• Large number of older SCD patients, placing strain on the system

• Adult "transition patients" ending up in the pediatric emergency room

• Lack of a medical home with anadult hematologist

– Result: suboptimal care with poor tracking of medication and transfusion histories

Page 11: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Ineffective use of healthcare system

Hemker BG, Brousseau DC, Yan K, Hoffmann RG, Panepinto JA. When children with sickle-cell disease becomes adults: lack of outpatient care leads to increased use of the emergency department. Am J Hematol. 2011 Oct;86(10):863-5. doi: 10.1002/ajh.22106. Epub 2011 Aug 3

During 5 year study:• Children = <18• Transition = turned 19• Young Adults = 19-30• Adults = >30

Page 12: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Readmission Rates Also Spike After Transition

12Brousseau DC, Owens PL, Mosso AL, et al. JAMA. 2010;303(13):1288-1294.

Approximately 80% of rehospitalizations were to the same hospital– 94% of pediatric readmissions– 77% of adult readmissions

Age range,years n

14-day Rehospitalization,n (95% CI)

30-day Rehospitalization,n (95% CI)

1-9 6895 7.3 (6.7-7.9) 12.8 (12.0-13.6)

10-17 8825 14.1 (13.4-14.8) 23.4 (22.5-24.3)

18-30 24,645 28.4 (27.8-29.0) 41.1 (40.5-41.7)

31-45 15,118 26.0 (25.3-26.7) 38.8 (38.0-39.6)

46-64 5160 15.3 (14.3-16.3) 27.1 (25.9-28.3)

>65 427 6.3 (4.0-8.6) 11.9 (8.8-15.0)

Page 13: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

The Transition Years Are A Vulnerable Time in Life For Many SCD Patients

Deaths in patients 18 years of age or older in the 940-patient Dallas newborn cohort– There were 7 deaths between 2002 and 2007, all of which occurred in transition-age

patients– Mean time between transition and death was 1.8 years

13Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Blood. 2010;115(17):3447–3452.

N/A, not applicable.

*Transition was delayed beyond 18 years due to chronic renal failure.

Patient no.

Age at transition, y

Age at death, y

Chronic complication of SCD Circumstances of death

1 N/A* 18.8 Renal failure; dialysis Found dead at home

2 17.9 19.2 None known Acute chest syndrome

3 18.0 18.3 None known Acute chest syndrome, refused transfusion

4 18.2 20.6 None knownFell in hospital while pregnant; cerebral hemorrhage

5 18.3 19.3 None knownAcute chest syndrome complicated by multiorgan failure syndrome

6 18.4 23.7 None known Presumed stroke

7 18.5 18.7 None known Multiorgan failure syndrome

Page 14: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Complications of SCD Increase As Patients Transition and RBC Transfusions Decrease

14Blinder MA, Vekeman F, Sasane M, et al. Pediatr Blood Cancer. 2013;60(5):828–835.

Any Complications

Mean Transfusions

PainInfection

5

4

3

2

1

0

Mea

n N

umbe

r w

ith >

1 D

iagn

osis

Per

Pat

ient

Per

Qua

rter

0 5045403530252015105

N= (555) (600) (662) (656) (505) (339) (274) (239) (172) (90)

Age

0.6

0.4

0.3

0.2

0.1

0

0.5

Mea

n N

umbe

r of

Tra

nsfu

sion

s E

vent

s an

d P

resc

riptio

ns P

er

Pat

ient

Per

Qua

rter

Increased frequency of complications correlates with a decrease in the

utilization of RBC transfusions and

hydroxyurea

Page 15: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Risk factors for unsuccessful transition

Associated with successful transition (1 adult visit):– Transferring to adult care <21 (p=0.008)– Distance <20 miles (p=0.01)– Severe phenotype - SS/Sβ0 (p=0.04)– Being on chronic transfusions (p=0.02)

32% did not transfer successfully

Andemariam et al. Identification of Risk Factors for an Unsuccessful Transition fromPediatric to Adult Sickle Cell Disease Care. Pediatr Blood Cancer 2014;61:697–701

Page 16: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Duke Experience

A retrospective database query was conducted among all Duke patients aged 18-23 years with a SCD outpatient encounters through Dec 2013

– Transfer was defined as having clinic visit in pediatrics followed by a subsequent visit in the adult clinic.

– Successful transfer was defined as having follow up care in adult hematology clinic for 1 year post-transfer.

Hill, S; Maslow, G; Walker, L; Johnson, S; Shah, N. Growing Pains – Determination of Transfer and Transition from Pediatrics to Adult Outpatient Clinics for Patients with Sickle Cell Disease (SCD) . ASH annual meeting 2014.

Page 17: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Duke ExperienceDatabase results

Hill, S; Maslow, G; Walker, L; Johnson, S; Shah, N. Growing Pains – Determination of Transfer and Transition from Pediatrics to Adult Outpatient Clinics for Patients with Sickle Cell Disease (SCD) . ASH annual meeting 2014.

Page 18: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Duke ExperienceValidation

Chart review of these patients– 26 (8%) had missing data on outpatient SCD

encounters– 48 (14%) SCD patients not followed by Duke

Hematology– 65 (19%) did not have a SCD diagnosis. 

_______________________________________

Total: – 139 (41%) records were excluded– 203 patients followed at Duke

Page 19: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Duke Experience

Classification:– Continued care in pediatrics– First visit in adults– Transferred to a non-Duke provider– Documented transfer to Duke adult provider (with

continued visits for 1 year)

“Lost to follow-up” status as greater than 6 months overdue

Page 20: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Duke Experience

5 (2%) are deceased (all <10 yo)

Continued care in pediatrics- Less than 6 months overdue for f/u

28 (14%)

First visit in adults 14 (6%)

Transferred to a non-Duke provider 19 (9%)

Transferred to adult hematology 60 (30%)

Lost to follow up 78 (38%)

Page 21: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Duke QI

Lost to follow up– Communicate with patient/family– Document status

– PCP– Specialty provider– Barriers to care– Insurance

Page 22: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

An Educational Model to Promote Successful Transition to Adulthood

Page 23: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Blum RW, Garell D, Hodgman CH, et al. J Adolesc Health. 1993;14(7):570-576.

A Definition of Transition

“Transition is a multifaceted, active process that attends to the medical, psychosocial, and educational/vocational needs of adolescents as they move from the child-focused to the adult- focused health-care system. Health transition facilitates transition in other areas as well (e.g., work, community, and the school).”

“Transition proceeds at different rates for different individuals and families (and programs)”

23

Page 24: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Components of a Transition Program

Comprehensive Approach– Must be a pre-defined program

Policies– Age = 18yo and graduation from high school

– 20yo if delayed graduation– 1-2 years in peds if attending college

– Education = must complete level 1 and 2 education in pediatrics

– mastery >80% on knowledge questionnaires

24Schwartz M, Tuchman LK, Hobbie WL, Ginsberg JP. Child Care Health Dev. 2011;37(6):883-895.

Page 25: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Components of a Transition Program

Components:– Medical Care – Adolescent/young adult Health Focus– Support - Case Management, Social, Psychological,

volunteers/educators– Education - Patient, Family, Providers

25Schwartz M, Tuchman LK, Hobbie WL, Ginsberg JP. Child Care Health Dev. 2011;37(6):883-895.

Page 26: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Levels of understanding

Level I (WHO)– Know who you are

Level II (WHAT)– Know what to do in different situations

Level III (WHERE)– Know where you are going

Level I 13-14 year old

Level II 15-16 year old

Level III 17-18 year old

Page 27: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

How much do you know about your Sickle Cell?

Page 28: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Planning for the Future:Levels of Patient Understanding

28

Level I(WHO)

Know who they are

Level II(WHAT)

Know what to do in different

Level II(WHERE)

Know where they are going

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

Page 29: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Level I(WHO)

Know who they are

WHOLevel I of Understanding

29

Level I13 to 14 years old

“I am _____, and I have sickle cell type ____.”

Page 30: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Level I UnderstandingPatients Aged 13 to 14 Years

Basic points to understand Shape of a sickle cell Genetics Types of sickle cell How sickle cell causes complications ‘Stressors’ that cause sickling

30

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

Page 31: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

What causes more ‘Sickling’?

Any stress on your body– Dehydration– Infection– Not breathing well– Temperature changes

Page 32: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Body happy = Blood happy!

Page 33: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

WHATLevel II of Understanding

33

Level II(WHAT)

Know what to do in different

Level II15 to 16 years old

“I am _____, and I have sickle cell type ____. Sickle cell is when your blood looks like a banana and can cause blood to have problems going places. Stress to the body can cause issues.

I know what I need to do when ____ happens with sickle cell.”

Page 34: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Level II UnderstandingPatients Aged 15 to 16 Years

Basic points to understand Types of blood cells Management of pain Medications taken daily

Warning signs for complications – Fever, shortness of breath, neurologic symptoms

Complications– Acute chest syndrome, stroke, infection,

priapism Sports and hydration

34

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

Page 35: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Patients Should Understand Implications of Their Lab Results

35

Hemoglobin

Carries Oxygen ‘Energy Cells’

White Blood Cells Transfusions, SF, LIC

Reticulocyte Count

Platelets

MCV

How big Reflects fetal hemoglobin HU effect

Reflect risk of chronic iron overload

How much blood is made

Stop bleeding Fight infection

MCV, mean corpuscular volume.

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

Page 36: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

What Patients Need to Know About:

36

Painmanagement

Shortnessof breath

Neurologic complications

• Know their medications– Have a pain action plan

• Take main pain medication withanti-inflammatory

• Drink fluids, rest, reduce‘stress’ to body

• Interplay between stress, swelling, and pain

• Can be an emergency

• Risk for acute chest syndrome

• Asthma increases their chances of having issues

• May need immediate transfusion or exchange transfusion

• Emergency

• Weakness, slurred speech, visual changes

• Need immediate transfusion or exchange transfusion

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

Page 37: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Level II(WHERE)

Know where they are going

WHERELEVEL III of Understanding

37

Level III17 to 18 years old

“I am _____, and I have sickle cell type ____. Sickle cell is when your blood looks like a banana and can cause blood to have problems going places. Stress to the body causes issues.

I know what I need to do when ____ happens with sickle cell.

I am going to ___ college/university and/or I am going to work ____. I know about what is bad for me and who/what are bad influences.”

Page 38: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Level III understandingPatients Aged 17 to 18 Years

Basic points to understand Health Maintenance School and/or work

(limits and resources) Insurance

Adult provider– Coordination of transfer– Inpatient management differences– Transfusions/exchange transfusion

38

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

Page 39: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Important Screenings for Health Maintenance

39

Routine dental exams Dilated eye exam

Urine microalbumin

Vaccinations

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

Page 40: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

What Patients Need to Know About:

40

School Work or volunteering

• Absences should be excused if they are absent for SCD issues

• Schools should work with them to get missed assignments

• Goals should be modified during illness or recovery

• Patients need to make sure they and their employers know their limits

• Patients should

– Hydrate

– Take breaks

– Understand when they need medications

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

Page 41: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Make Sure Patients Understand Their Insurance Options

Patients need to understand that seeking treatment without insurance will

result in large medical bills

– Leading cause for young adults to end up bankrupt is large, unexpected medical bills

Patients should talk to a social worker or regional public health sickle cell

educators about resources and options.

41

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

Page 42: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Inpatient care Medications Transfusions/exchange transfusion decisions

and tracking Screening and monitoring Resources

Coordination of Care With the Adult Provider is Crucial

Agree upon the transfer process and time necessary for transition should be agreed upon by both

Outline the coordination of care before and after

42

Adult provider

(hematologist)Pediatric

provider

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

Page 43: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Know your Sickle Cell

43

Level I13 to 14 years old

Level II15 to 16 years old

Level III17 to 18 years old

I am ____ and I have sickle cell type ____.

WHO: WHAT:

I know what to do when ___ happens.

WHERE:

I know where I am going, to ___ college/university and/or working at ___

Page 44: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Evidence of knowledge

Quizzes– Level 1 - Who, median 9 (range 7-10)– Level 2 - What, median 10 (range 8-10)– Level 3 - Where, median 8 (range 4-10)

Working on ‘All star’ Quizzes

Page 45: Sickling smoothly through life… Educating patients about transition Nirmish Shah, MD Assistant Professor Director of Sickle Cell Transition Program Duke

Questions???

Transition to adulthood